Prognosis
The prognosis is very unfavorable (infaust), since glioblastomas are fatal within a few weeks if left untreated. Even maximum therapy for glioblastomas only leads to a survival time of 6 months to 2 years. The one-year survival rate is 30-40%, the two-year survival rate is 10% and the five-year survival rate is 3%.
Due to improved therapeutic strategies with increased involvement of chemotherapy with the cytostatic drug temozolomide, the two-year survival rate has already been increased to 26%. Age and clinical symptoms at the beginning of therapy are considered to be the most important prognostic factors. In general, young patients with optimal tumor removal, a good so-called mini-mental state score (dementia score) and a methylated MGMT promoter (DNA repair protein) in connection with temozolomide therapy have a more favorable prognosis.
Prophylaxis
Since the risk factors and triggers for the development of glioblastomas are largely unknown, there are also no recommendations for prevention.
Summary
Glioblastoma multiforme accounts for 25% of all primary brain tumors. It is highly malignant, often with infiltrating, multi-site (multifocal) growth in the cerebral hemispheres, occasionally on both sides over the bar (butterfly glioma). Due to the formation of pathological vessels, the tumor tends to hemorrhage, which leads to an apoplectic glioma.
Symptoms are headaches, nausea, paralysis, psychological changes and epileptic seizures. The most important means of diagnosis are the imaging procedures CT and MRI. Therapy involves surgical removal of the tumor as completely as possible, followed by radiation and chemotherapy. The prognosis is infaust with death after 12 months on average.
